Author Archives: zymecom

← Older posts Newer posts →

Horizon Discovery signs license agreement with Glenmark Pharmaceuticals for GS knockout CHO cell line for manufacture of biotherapeutics

Posted on by zymecom

Glenmark signs full commercial-use license for Horizon’s gene-edited CHO cells Cambridge, UK, 30 September 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced … Continue reading

Posted in News from Zyme and the companies we work with | Comments Off on Horizon Discovery signs license agreement with Glenmark Pharmaceuticals for GS knockout CHO cell line for manufacture of biotherapeutics

Iksuda Therapeutics presents first data on lead antibody drug conjugate, demonstrating effective tumour regression

Posted on by zymecom

IKS01 shows marked anti-tumour efficacy in pre-clinical models of ovarian and lung cancer Data presented at ESMO Congress 2019 in Barcelona, Spain Newcastle, UK, 30 September 2019: Iksuda Therapeutics (Iksuda), a developer of next generation Antibody Drug Conjugates (ADCs), today … Continue reading

Posted in News from Zyme and the companies we work with | Comments Off on Iksuda Therapeutics presents first data on lead antibody drug conjugate, demonstrating effective tumour regression

H.E.L. Group appoints new CEO and secures £5.9 million GBP ($7.3 million USD) investment

Posted on by zymecom

Louise Madden joins as CEO to drive Company’s growth strategy Investment by Connection Capital supports H.E.L. Group in servicing global demand for its products, including fast-growth markets in Asia Borehamwood, UK, 25 September 2019: H.E.L. Group Ltd, a global manufacturer … Continue reading

Posted in News from Zyme and the companies we work with | Comments Off on H.E.L. Group appoints new CEO and secures £5.9 million GBP ($7.3 million USD) investment

St George Street Capital agrees deal with AstraZeneca to drive science to patients in need

Posted on by zymecom

Harpenden, UK, 24 September 2019: St George Street Capital (SGSC), a UK registered charity, has signed a license agreement with AstraZeneca to develop two compounds in the clinic: one for idiopathic male infertility, and the other for renal transplant rejection. … Continue reading

Posted in News from Zyme and the companies we work with | Comments Off on St George Street Capital agrees deal with AstraZeneca to drive science to patients in need

FUJIFILM Irvine Scientific Introduces Vit Kit-NX, the Next Generation of Vitrification Media Solutions

Posted on by zymecom

SANTA ANA, California, 24 September, 2019: FUJIFILM Irvine Scientific, Inc., a world leader in the innovation, development, and manufacture of cell culture media and Assisted Reproductive Technologies (ART), today announced the release of Vit Kit-NX – the latest addition to … Continue reading

Posted in News from Zyme and the companies we work with | Comments Off on FUJIFILM Irvine Scientific Introduces Vit Kit-NX, the Next Generation of Vitrification Media Solutions

Source BioScience invest €585,000 in stability storage with new state-of-the-art microbiology and sterility testing labs

Posted on by zymecom

New facilities expand services offering to Irish and International customers Nottingham, UK, 16 September 2019: Source Bioscience, an international provider of integrated laboratory services and products, today announced it has invested €585,000 in microbiology and sterility testing labs at its … Continue reading

Posted in News from Zyme and the companies we work with | Comments Off on Source BioScience invest €585,000 in stability storage with new state-of-the-art microbiology and sterility testing labs

Mologic and University College London Hospitals collaborating in major clinical trial for early detection of sepsis

Posted on by zymecom

Study aims to develop a rapid point-of-care diagnostic based on multiple biomarkers to detect emergent sepsis Observational study led by Mervyn Singer, Professor of Intensive Care Medicine and Dr David Brealey, Consultant in Intensive Care Bedfordshire, UK, 13 September 2019: … Continue reading

Posted in News from Zyme and the companies we work with | Comments Off on Mologic and University College London Hospitals collaborating in major clinical trial for early detection of sepsis

BIA Separations introduces Cornerstone AAV Process Development Service to accelerate gene therapy production

Posted on by zymecom

BIA Separations introduces Cornerstone AAV Process Development Service to accelerate gene therapy production CORNERSTONE program integrates process development expertise and novel technology to remove development bottlenecks in the manufacture of Gene Therapy Medicinal Products (GTMPs) Portfolio includes novel CIMasphere™ technology … Continue reading

Posted in News from Zyme and the companies we work with | Comments Off on BIA Separations introduces Cornerstone AAV Process Development Service to accelerate gene therapy production

FUJIFILM Irvine Scientific Launches BalanCD Gal Supplement for biotherapeutic development

Posted on by zymecom

Delivers enhanced galactosylation for improved protein quality, and antibody binding and function  SANTA ANA, California, 10 September, 2019: FUJIFILM Irvine Scientific, Inc., a world leader in the optimization, development and manufacture of cell culture media and industrial cell culture solutions, … Continue reading

Posted in News from Zyme and the companies we work with | Comments Off on FUJIFILM Irvine Scientific Launches BalanCD Gal Supplement for biotherapeutic development

Gyros Protein Technologies introduces Gyrolab p24 Kit to support the cell and gene therapy market

Posted on by zymecom

Ready-to-use kit enables lentivirus titer determinations during the manufacture of lentivirus vectors Uppsala, Sweden, 09 September 2019: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, today announced the introduction of … Continue reading

Posted in News from Zyme and the companies we work with | Comments Off on Gyros Protein Technologies introduces Gyrolab p24 Kit to support the cell and gene therapy market ← Older posts Newer posts →
  • People

    An experienced senior team of specialists in life science communications, with expertise gained in-house and agency side, offering the flexibility to support both early-stage companies and large multinationals.

  • Keep in touch

    +44(0) 1223 968 920

    info@zymecommunications.com


     

  • Upcoming Events

    Zyme Communications will be providing support for its clients attending the following events:

    Neuroscience 2019

    When: Sat October 19 09:00 - Wed October 23 18:00
    Where: Chicago, USA

    ELRIG Drug Discovery

    When: Tue November 5 09:00 - Wed November 6 18:00
    Where: Liverpool, UK